- Search Results
 
 
Ebola Vaccines Phase 2 Study Targets 1,500 Volunteers
Date Uploaded: Mar 28, 2015

Montserrado County Flag

 

 

Ebola Vaccines Phase 2 Study Targets 1,500 Volunteers

By Joseph Toe, LINA

MONROVIA, March 27 (LINA) - A total of 1,500 persons will be enrolled in Phase 2 of the Partnership for Research on Ebola Vaccines in Liberia (PREVAIL) study, according to the Liberian-US joint clinical research team.

The team noted that the number, which more than doubles the 600 participants that were enrolled in Phase 1, will also increase the percentage of women in the study.

The above is part of several initiatives being developed by the team in addition to exploring the possibility of sharing the Phase 3 of the PREFVAIL study with other countries within the West African sub-region.

Addressing the daily Ebola press briefing of the Ministry of Information at the ministry Thursday, co-principal investigator on the team, Dr. Stephen Kennedy, said at least two additional blood samples would be obtained from all participants for at least one year to examine the durability of the immune responses.

Kennedy pointed out that participants should continue be enrolled in the Phase 2 PREVAIL study at Redemption Hospital through late April and follow up with them for at least six to 12 months post-vaccination to determine the durability of the immune responses.

According to him, these proposed changes are being reviewed by the US Food and Drug Administration and Liberia and US Institutional Review Boards.

Kennedy pointed out that Phase 3 component of the study had planned to enroll about 27,000 Liberians at risk of the Ebola virus infection.

He noted, however, that as a result of Liberia’s successful infection control and prevention strategy targeting Ebola, there has been only one new case since February 19, prompting the team to decide it is scientifically appropriate to develop additional vaccine sites in other West African countries to consider co-sharing the Phase 3 study.

“Discussions are currently underway to explore that possibility,” he said.

It will be recalled the vaccines, ChAd3-EBO-Z, developed by GlaxoSmithKline or VSV-ZEBOV, from NewLink Genetics/Merck versus a saltwater placebo injection were introduced in the country early this year.

LINA

latest headlines
Agric Minister Wiles On Extension Services
Agriculture Minister Seklau E. Wiles says effective extension services are crucial to the development of the country's agriculture sector. ...more
Global Communities, Coca-Cola Foundation Dedicate 32 Hand Pumps
The Golden Triangle Partnership Fund under the Coca-Cola System in collaboration with Global Communities has turned over thirty-two newly-constru ...more
Health Authorities Shut 55 Mineral Water Firms
The Ministry of Health and National Public Health Institute of Liberia (NPHIL) have shut down 55 mineral water companies in Monrovia and its envi ...more
ECOWAS Network Of Elections Commissioners Visits Supreme Court
A high-power delegation from the ECOWAS Network of Elections Commissioners (ECONEC) Tuesday paid a courtesy call on the Chief Justice and Associa ...more
Supreme Court Upholds NEC's Ruling; Disqualifies Kamara
The Supreme Court has disqualified the Assistant Minister for Administration at the Ministry of Posts and Telecommunications, Abu Bana Kamara, fr ...more
Bong Citizens Recommit To Supporting VP Boakai's Bid
The leadership of Bong County has re-iterated its commitment to supporting the presidential bid of Vice President Joseph Boakai. ...more
 
All rights reserved © 2013 - 2014
Liberia News Agency